Hence, Natarajan et al. reported that the greatest uptake of 64Cu-DOTA-anti-PD-1-mAb was achieved at 48 h post-injection, with a tumor-to-muscle uptake ratio of 11 in mice bearing B16-F10 melanoma tumors [297]. The gene discussed is PDCD1; the disease is neoplasm.